NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK

• Auteurs principaux: Helene Cawston (Auteur), Francois Bourhis (Auteur), Jennifer Eriksson (Auteur), Pierfrancesco Ruffo (Auteur), Paolo D'Agostino (Auteur), Marco Turini (Auteur), Lee Schwartzberg (Auteur), Alistair McGuire (Auteur)
• Format: Livre
• Publié: BioExcel Publishing Ltd, 2017-03-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Background: The objective was to evaluate the cost-effectiveness of NEPA, an oral fixed combination netupitant (NETU, 300 mg) and palonosetron (PA, 0.5 mg) compared with aprepitant and palonosetron (APPA) or palonosetron (PA) alone, to prevent chemotherapy-induced nausea and vomiting (CINV) in patie...